Table 3.
Clinical outcome by cohort
| Unadjusted analysis |
P | ||||||
|---|---|---|---|---|---|---|---|
| Allogeneic HCT, % (n = 98) |
Non-HCT, % (n = 132) |
||||||
| 1 y | 3 y | 5 y | 1 y | 3 y | 5 y | ||
| OS | 90 | 76 | 67 | 92 | 72 | 59 | .26 |
| RFS | 88 | 70 | 62 | 85 | 65 | 54 | .15 |
| CIR | 2 | 13 | 16 | 8 | 23 | 29 | .01 |
| NRM | 10 | 17 | 22 | 7 | 13 | 18 | .32 |
| GRFS | 59 | 33 | 30 | 85 | 65 | 54 | <.0001 |
| PS matched analysis |
P | ||||||
|---|---|---|---|---|---|---|---|
| Allogeneic HCT, % (n = 58) |
Non-HCT, % (n = 58) |
||||||
| 1 y | 3 y | 5 y | 1 y | 3 y | 5 y | ||
| OS | 91 | 77 | 68 | 93 | 73 | 61 | .63 |
| RFS | 88 | 67 | 63 | 84 | 64 | 52 | .42 |
| CIR | 3 | 16 | 16 | 11 | 27 | 36 | .001 |
| NRM | 9 | 17 | 21 | 5 | 9 | 11 | .06 |
| GRFS | 57 | 29 | 25 | 84 | 64 | 52 | .0001 |
Includes 1-, 3-, and 5-y OS, RFS, CIR, NRM, and GRFS.